Skip to main content


Generic name: glecaprevir and pibrentasvir (glec A pre vir and pi BRENT as vir)
Brand name: Mavyret
Drug class: Antiviral combinations

Medically reviewed by Judith Stewart, BPharm. Last updated on Nov 3, 2020.

What is Mavyret?

Mavyret contains a combination of glecaprevir and pibrentasvir. Glecaprevir and pibrentasvir are antiviral medications that prevent hepatitis C virus (HCV) from multiplying in your body.

Mavyret is used to treat chronic hepatitis C in adults and children over 12 years with HCV genotype 1, 2, 3, 4, 5, or 6.

Mavyret is usually given after other medicines have been tried without success.


You should not use Mavyret if you have severe liver disease, or if you also take atazanavir or rifampin.

If you've ever had hepatitis B, it may become active or get worse after you stop using Mavyret. You may need frequent liver function tests for several months.

Before taking this medicine

You should not use Mavyret if you are allergic to glecaprevir or pibrentasvir, or if:

  • you have severe liver disease; or

  • you also take atazanavir or rifampin.

To make sure Mavyret is safe for you, tell your doctor if you have ever had:

  • hepatitis B;

  • liver problems other than hepatitis;

  • a liver or kidney transplant;

  • HIV (human immunodeficiency virus); or

  • an opioid addiction or past use of injected drugs.

Tell your doctor if you are pregnant or breastfeeding.

Mavyret should not be given to a child younger than 12 years old, or weighing less than 99 pounds (45 kilograms).

It may not be safe to breast-feed while using this medicine. Ask your doctor about any risk.

How should I take Mavyret?

Take Mavyret exactly as prescribed by your doctor. Follow all directions on your prescription label and read all medication guides or instruction sheets.

Your doctor will perform blood tests to make sure you do not have conditions that would prevent you from safely using Mavyret.

Mavyret is usually taken as 3 tablets daily, taken all at once, for 8 to 16 weeks.

Take with food.

You will need frequent blood tests to check your liver function.

You should not stop using Mavyret suddenly. Stopping suddenly could make your condition harder to treat with hepatitis C antiviral medicine.

Use all hepatitis C medications as directed and read all medication guides you receive. Do not change your dose or stop using a medicine without your doctor's advice. Every person with hepatitis C should remain under the care of a doctor.

If you've ever had hepatitis B, this virus may become active or get worse in the months after you stop using Mavyret. You may need frequent liver function tests while using this medicine and for several months after your last dose.

Store this medicine in the original container at room temperature away from moisture and heat. Keep each tablet in the foil blister pack until you are ready to take it.

Dosing information

Usual Adult Dose of Mavyret for Chronic Hepatitis C:

3 tablets orally once a day with food

Duration of Therapy:
HCV genotype 1, 2, 3, 4, 5, or 6:
-No cirrhosis: 8 weeks
-Compensated cirrhosis (Child-Pugh A): 12 weeks

HCV genotype 1 (prior therapy with regimen containing an NS5A inhibitor without prior therapy with an NS3/4A protease inhibitor):
-No cirrhosis: 16 weeks
-Compensated cirrhosis (Child-Pugh A): 16 weeks

HCV genotype 1 (prior therapy with regimen containing an NS3/4A protease inhibitor without prior therapy with an NS5A inhibitor):
-No cirrhosis: 12 weeks
-Compensated cirrhosis (Child-Pugh A): 12 weeks

HCV genotype 1, 2, 4, 5, or 6 (prior therapy with regimen containing PRS):
-No cirrhosis: 8 weeks
-Compensated cirrhosis (Child-Pugh A): 12 weeks

HCV genotype 3 (prior therapy with regimen containing PRS):
-No cirrhosis: 16 weeks
-Compensated cirrhosis (Child-Pugh A): 16 weeks

-Recommended for HCV mono-infected and HCV/HIV-1-coinfected patients with compensated liver disease (with or without cirrhosis)
-NS5A: Nonstructural protein 5A; NS3/4A: Nonstructural protein 3/4A
-In clinical trials, patients with prior NS5A inhibitor experience were treated with regimens containing ledipasvir-sofosbuvir or daclatasvir with pegylated interferon and ribavirin.
-In clinical trials, patients with prior NS3/4A protease inhibitor experience were treated with regimens containing simeprevir with sofosbuvir, or simeprevir, boceprevir, or telaprevir with pegylated interferon and ribavirin.
-PRS: Prior treatment experience with regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir without prior treatment experience with an HCV NS3/4A protease inhibitor or NS5A inhibitor

-For the treatment of patients with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A)
-For the treatment of HCV genotype 1-infected patients with prior treatment using a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both

What happens if I miss a dose?

Use the medicine as soon as you can, but skip the missed dose if you are more than 18 hours late for the dose. Do not use two doses at one time.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What to avoid

Using this medicine will not prevent your disease from spreading. Do not have unprotected sex or share razors or toothbrushes. Talk with your doctor about safe ways to prevent HCV transmission during sex. Sharing drug or medicine needles is never safe, even for a healthy person.

Mavyret side effects

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

In rare cases, Mavyret may cause serious liver injury. Call your doctor right away if you have symptoms such as:

  • right-sided upper stomach pain;

  • nausea, vomiting, loss of appetite;

  • confusion, tiredness, feeling light-headed;

  • easy bruising or bleeding, vomiting blood;

  • diarrhea, black or bloody stools;

  • dark urine; or

  • yellowing of your skin or eyes.

Common side effects may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect Mavyret?

Sometimes it is not safe to use certain medications at the same time. Some drugs can affect your blood levels of other drugs you take, which may increase side effects or make the medications less effective.

Other drugs can interact with glecaprevir and pibrentasvir, and some drugs should not be used at the same time. Tell your doctor about all your current medicines and any medicine you start or stop using. This includes prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed here.

Popular FAQ

Some of the main differences between hepatitis B and C are:

  • Hepatitis B virus can be prevented with a vaccine, but not hepatitis C.
  • Hepatitis B and C are different viruses, but you can have both hepatitis B and hepatitis C at the same time.
  • Over 90% of people infected with hepatitis C who have not received treatment can be cured with 8 to 12 weeks of oral medications, but treatment for hepatitis B, if needed, may be long-term or lifelong.
  • There is no cure for hepatitis B, but once you recover from acute hepatitis B, you develop antibodies that protect you from the virus for life.
Continue reading

Alcohol use in patients with hepatitis C virus (HCV) may result in a quicker progression to cirrhosis and liver cancer. Mavyret (glecaprevir-pibrentasvir) is used to treat patients with advancing HCV. Because there is a link between a more rapid progression of liver disease and the use of alcohol, clinicians typically suggest that all patients with HCV avoid alcohol use. Continue reading

The list price of Mavyret (glecaprevir and pibrentasvir) tablets for a 4-week supply is $13,200 or $26,400 per 8-week treatment course, according to AbbVie, the manufacturer. However, your out-of-pocket cost may be significantly less based on your public or private insurance coverage and copay. AbbVie’s Patient Assistance Plan may also lower your costs based on eligibility. Continue reading

Mavyret is reported to have some advantages over Harvoni including the number of hepatitis C virus (HCV) genotypes it covers, the length of treatment required, and the cost of a course of treatment. Continue reading

How long you are treated with Mavyret depends upon your liver function, previous treatments, and other medical conditions you may have. Your doctor will decide the most appropriate length of time for your treatment regimen. In general, treatment can range from 8 to 16 weeks. Continue reading

It is generally accepted that it takes 5.5 half-lives for a drug to be removed enough from the body that it is thought to have no clinical effect. After taking Mavyret, it’s therefore expected to take 33 hours to eliminate glecaprevir and 71.5 hours to eliminate pibrentasvir. Continue reading

While there’s no known interaction between ibuprofen and Mavyret, ibuprofen may not be suitable if you have hepatitis C virus (HCV) infection. If you are taking Mavyret, check with your doctor before taking ibuprofen.

HCV slowly damages the liver and ibuprofen can also adversely affect the liver, causing liver enzymes to become elevated and in rare cases severe liver reactions and liver failure. In some cases the combination of ibuprofen and chronic hepatitis C has been reported to lead to drug-induced liver injury or damage (hepatotoxicity). Continue reading

Further information

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Mavyret only for the indication prescribed.

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.